Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
Key facts
- Who runs it
- Valenta Pharm JSC
- Where
- Russia11 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 300 people, planned
- Started
- 24 Oct 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ingavirin Forte, 90 mg + 5 mg, Capsules
- Ingavirin Forte, 90 mg + 10 mg, Capsules
- Ingavirin Forte, 90 mg + 20 mg, Capsules
- Ingavirin, 90 mg, Capsules
- Placebo
- Record updated
- 19 February 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 42 criteriaShow less
Who can take part
- Voluntarily and personally signed Informed Consent Form (ICF) by a participant obtained prior to the conduct of any study-related procedure
- Males and females aged 18 to 65 years (inclusive) at the time of signing the ICF
- Subjects with influenza or other acute respiratory viral infections confirmed by polymerase chain reaction (PCR)
- Presence of clinically significant signs of influenza or acute respiratory viral infections at screening:; Body temperature >38,0 °С at randomization, with no intake NSAID within 12 hours before randomization; Presence of at least two of the following symptoms of influenza or other acute respiratory viral infections (cough, rhinorrhea, sore throat, or a throat irritation) each rated non less than 6 points on a numeric rating scale (NRS); Presence of at least one of the following systemic manifestations of influenza or other acute respiratory viral infections (headache, myalgia, or general weakness) rated non less than 6 points on a numeric rating scale (NRS)
- Duration of illness from symptoms onset to administration of the first dose of investigational medical product or comparator is ≤ 48 hours
- No clinical indications for hospitalization at the time of study enrollment
- Consent to use adequate contraceptive methods throughout the study and for 30 days after study completion. The follwing subjects are eligible for inclusion in the study:; Females of childbearing potential must have a negative pregnancy test and use one of the folliwing adequate contraceptive methods: sexual abstinence, condom combined with spermicide or hormonal contraceptives, contraceptive subdermal implant, intrauterine hormonal system, intrauterine device. Females not of childbearing potential (i.e., with a history of hysterectomy, bilateral oophorectomy, bilateral tubal ligation, comfirmed infertility, or ≥ 2 of menopause) are also eligible for participation; Males with reptoductive potential must use one of the folliwing adequate contraceptive methods: sexual abstinence, condom combined with spermicide or hormonal contraceptives. Males with infertility or a history of vasectomy are also eligible for participation
Who cannot take part
- Administration of antibiotics, antiviral (including Ingavirin), or immunomodulatory agents within 48 hours prior to study, and/or anticipated need for any of these agents during the study
- Vaccination within 90 days prior to study enrollment
- Participation in another clinical trial within 3 months prior to screening
- Investigator-determined need for a concomitant therapy explicitly prohibited by the protocol of clinical study
- Subject's use of a therapy prohibited by the protocol
- Clinically significant allergic history
- Hypersensitivity to active substances of medical produtcs Ingavirin and Ingavirin forte, and/or to any excipient contaned in the investigational medicinal product or comparator
- Clinical suspicion of pneumonia of any etiology, or other bacterial infection (e.g. sinusitis, otitis media, urinary tract infection, meningitis, sepsis) requiring initiation for antibacterial therapy
- History of vasomotor rhinitis
- Uncontrolled diabetes mellitus
- History of autoimmune diseases
- Current or past HIV, syphilis, hepatitis B and/or C, or tuberculosis
- Known or suspected history of alcohol, psychotropic drug, or substance abuse or dependence
- History of chronic respiratory disease, including but not limited to: chronic obstructive pulmonary disease (COPD), asthma, chronic bronchitis, diffuse panbronchiolitis, pulmonary emphysema, or pulmonary fibrosis
- Chronic heart failure, New York Heart Association (NYHA) functional class III or IV
- Current or past psychiatric disoder
- Any clinically significant cardiovascular, renal, hepatic, gastrointestinal , endocrine, or neurological disoder, including severe uncompensated chronic conditions (e.g., chronic kidney disease, chronic liver disease) or acute illness, or any other medical or psychiatric condition that, in investigator's opinion, could pose a safety risk to the subject if they participate in the study
- Other conditions which, in the judgment of the investigator, could compromise the subject's participation in the study or pose an undue risk
- Emergence during the study of conditions or events that jeopardize subject safety (e.g., hypersensitivity reactions, serious adverse events [SAEs]) or, in the investigator's medical judgment, worsen the subject's prognosis or preclude further participation in the clinical study
- Confirmed diagnosis of COVID-19
- Occurrence during the study of any other condition that precludes adherence to the protocol
- Known galactose intolerance, lactase deficiency, or glucose-galactose malabsorption
- Intolerance to active substances of medical produtcs Ingavirin and Ingavirin forte, and/or to any excipient contaned in the investigational medicinal product or comparator
- Nasal obstruction due to structural pathology, such as sequelae of nasal trauma, nasal polyps, septal deviation, or other organic causes
- Obesity, class II or III (body mass index ≥35 kg/m²)
- Pregnancy or lactation
- Positive test for SARS-CoV-2 at screening
- Subject's refusal to use an adequate method of contraception or to practice continuous sexual abstinence throughout the study and for 30 days after study completion
- Subject's decision to withdraw from the study (withdrawal of informed consent)
- Investigator's decision to discontinue the subject from the study in the subject's best interest
- Positive urine test for beta-human chorionic gonadotropin (β-hCG) in females of childbearing potential
- Lack of adequate cooperation by the subject with the investigator during the study
- Incorrect inclusion of a subject who does not meet the protocol-specified inclusion and/or exclusion criteria
- Major deviation from the treatment regimen, defined as:; Missing two or more consecutive doses of the investigational medicinal product (IMP) or comparator; Total intake of fewer than 80% or more than 120% of the planned total number of capsules (full course includes 10 capsules)
- Subject's death
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial is currently available in Russia.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of this study is to investigate the efficacy, safety, and tolerability of investigational product Ingavirin forte capsules (Valenta Pharm JSC) administered at different doses compared with medicinal product Ingavirin, 90 mg, capsules (Valenta Pharm JSC) in subjects with influenza or other acute respiratory viral infections (ARVIs).
The 5 groups in the trial
- Ingavirin Forte, 90 mg + 5 mg, CapsulesTreatment being tested
Subjects will receive Ingavirin Forte, 90 mg + 5 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.
- Ingavirin Forte, 90 mg + 10 mg, CapsulesTreatment being tested
Subjects will receive Ingavirin Forte, 90 mg + 10 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.
- Ingavirin Forte, 90 mg + 20 mg, CapsulesTreatment being tested
Subjects will receive Ingavirin Forte, 90 mg + 20 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.
- Ingavirin Forte, 90 mg , CapsulesExisting treatment, for comparison
Subjects will receive Ingavirin, 90 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.
Treatment: Ingavirin, 90 mg, Capsules
- Placebo, CapsulesPlacebo, for comparison
Subjects will receive Placebo, 1 capsule twice daily (morning and evening), for 5 consecutive days.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of the Investigational Product Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
- Criteria questions
- Built from NCT07420985, who can take part
- Record updated
- 19 February 2026